Andere Sprachen JW (Cayman) Therapeutics Co. Ltd

Aktien

A2QFV3

KYG5210T1040

2126

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:05 02.07.2024			% 5 Tage	% 1. Jan.
1.89 ^HKD	-3.57%		-6.90%	-16.37%

30.05.	JW (Cayman) Therapeutics präsentiert Studiendaten von SLE-Medikament auf Rheumatologie-Kongress	MT
30.05.	JW (Cayman) Therapeutics Co. Ltd. gibt auf dem Kongress EURAL 2024 ein Forschungs- und Entwicklungs-Update mit vorläufigen klinischen Daten zu Relma-Cel Injektion bei Erwachsenen mit aktivem systemischen Lupus erythematodes in China bekannt	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress	30.05.
JW (Cayman) Therapeutics Presents Trial Data from SLE Drug at Rheumatology Congress	30.05.
JW Therapeutics Co. Ltd Announces Research and Development Update Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China At the EURAL 2024 Congress	30.05.
JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	20.03.
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	20.03.
China Regulator Accepts JK Therapeutics' Supplemental License Application for Lymphoma Therapy	05.01.
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva in Patients with Relapsed or Refractory Mantle Cell Lymphoma	04.01.
JW (Cayman) Therapeutics Signs Collaboration Deal for Development of Autoimmune Disease Treatment	03.01.
JW Therapeutics Announces Exclusive Collaboration with 2Seventy Bio for Autoimmune Disease Car-T Therapy	02.01.
JW Therapeutics CFO Resigns	18.12.
JW Therapeutics Co. Ltd Announces Resignation of Xin Fu as Chief Financial Officer	15.12.
JW (Cayman) Therapeutics to Expand Strategic Alliance with Cell and Gene Therapy Firm	13.09.23
2Seventy Bio, Inc. and Jw Therapeutics Announce Intent to Expand Strategic Partnership to Accelerate the Research and Development of T Cell-Based Immunotherapies and Autoimmune Therapies	12.09.23
JW Therapeutics Co. Ltd Announces Board Changes	30.08.23
JW Therapeutics' H1 Attributable Loss Narrows on Higher Revenue	29.08.23
JW Therapeutics Co. Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	29.08.23
JW (Cayman) Therapeutics to Buy Viral Vector from Substantial Shareholder	22.05.23
China Gives Investigational New Drug Clearance to JW Therapeutics' Anti-Lupus Injection; Shares Rise 7%	11.04.23
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus	10.04.23
JW Therapeutics' 2022 Loss Widens	30.03.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen JW (Cayman) Therapeutics Co. Ltd

Aktien

A2QFV3

KYG5210T1040

2126

Andere Sprachen

Filter